Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  donor lymphocytes
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-22 of 22 for your search:
Start Over
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 to 75
Sponsor: Other
Protocol IDs: CN301-XYK-001, NCT01690507
Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: CN301-XYK-002, NCT01758367
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2012-0501, NCI-2013-01666, NCT01875237
Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 8 to 61
Sponsor: Other
Protocol IDs: 307-CTC-DC/CIK-Leukemia, NCT01956630
Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and under
Sponsor: Other
Protocol IDs: I.2013.004, NCT02328885
Cytokine Induced Killer (CIK) Cells In Leukemia Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: Eudract number: 2008-003185-26, NCT01186809
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 69
Sponsor: Other
Protocol IDs: UCL/10/0241, LRF-09041, EU-21081, CRUK-UCL-PROT4, ProT4 (UCL/10/0241), PROT4, CRUK-UCL-10/0241, NCT01240525
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: UCL/10/0411, NCT01597219
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BrUOG 273, NCT01685606
Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13D.127, 2012-104, NCT01871441
Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: H-1305-6130491, NCT01925118
Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13D.352, 2013-031, NCT01982682
Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: STIR Trial, NCT02100891
Host Dendritic Cells in Allograft Patients
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 08-0906, NCT00935597
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010LS063, MT2010-10, 1009M89012, NCT01385423
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Phase: Phase I
Type: Supportive care, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: BMT243, NCI-2012-00044, SU-01272012-9028, 22626, NCT01523223
Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant
Phase: Phase I
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Pro00003975, NCT01627275
Adoptive Transfer of Haplo-identical DLI for AML and MDS
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 55 and over
Sponsor: Other
Protocol IDs: Pro00043247, NCT02046122
Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation
Phase: Phase I
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: SCTL141501, PG1061252, NCT02189824
AML Therapy With Irradiated Allogeneic Cells
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and older
Sponsor: NCI, Other
Protocol IDs: 021208, NCI-2013-02408, Pro2013002693, P30CA072720, NCT02105116
IFN-DLI for Relapsed Acute Leukemia After Allo-SCT
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 09414, NCT02331706
Start Over